• Nenhum resultado encontrado

Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome

N/A
N/A
Protected

Academic year: 2017

Share "Prevalence of the metabolic syndrome and its components in Brazilian women with polycystic ovary syndrome"

Copied!
7
0
0

Texto

(1)

Prevalence of the metabolic syndrome and its

components in Brazilian women with polycystic

ovary syndrome

Elvira Maria Mafaldo Soares, M.D.,aGeorge Dantas Azevedo, Ph.D.,b

Rafael Goncxalves Nobrega Gadelha, M.D., aTelma Maria Araujo Moura Lemos, Ph.D., c and Tecia Maria Oliveira Maranh ao, Ph.D.~ a

aDepartamento de Tocoginecologia, Maternidade Escola Janu

ario Cicco;bDepartamento de Morfologia, Centro de Bioci ^ encias; andcDepartamento de An

alises Clınicas, Centro de Ci^encias da Saude, Programa de Pos-graduacx~ao em Ci^encias da Saude, Universidade Federal do Rio Grande do Norte, Natal-RN, Brazil

Objective: To determine the prevalence of the metabolic syndrome (MetS) and its components in Brazilian women with polycystic ovary syndrome (PCOS).

Design: Cross-sectional study.

Setting: University Hospital, Federal University of Rio Grande do Norte, Natal-RN, Brazil. Patient(s): 102 women with PCOS by the Rotterdam consensus criteria.

Intervention(s): None.

Main Outcome Measure(s): Clinical and biochemical parameters for MetS as defined by the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III).

Result(s): The prevalence for individual components of MetS were high-density lipoprotein cholesterol level<50 mg/dL in 69.6%, waist circumferenceR88 cm in 57.9%, triglyceride levelR150 mg/dL in 31.7%, blood pressure

R130/85 mm Hg in 18.6%, and fasting glucose concentrationsR110 mg/dL in 2.9%. Three or more of these individual criteria were present in 29 (28.4%) of the patients. The prevalence of MetS increased with body mass index: 3.2%, 19.2% and 52.3% for normal, overweight, and obese women, respectively.

Conclusion(s): These findings indicate that Brazilian women with PCOS have a high prevalence of MetS and its individual components, particularly a decreased high-density lipoprotein cholesterol level. Thus, these women are at increased risk of diabetes mellitus and cardiovascular disease. (Fertil SterilÒ2008;89:649–55.Ó2008 by

Amer-ican Society for Reproductive Medicine.)

Key Words: Metabolic syndrome, polycystic ovary syndrome, cardiovascular disease

Polycystic ovary syndrome (PCOS) is one of the most com-mon endocrine diseases in women, affecting approximately 5% to 8% of premenopausal women(1–3). This ovarian dis-function syndrome is characterized by chronic anovulation, oligomenorrhea or amenorrhea, hyperandrogenism, infertil-ity, and polycystic ovary morphology(4). Additionally, it is recognized to have a metabolic component consisting of hy-perinsulinemic insulin resistance; this finding has led to the correlation of PCOS with increased cardiovascular disease risk, which occurs in both lean and obese women with the disorder(5, 6).

The metabolic syndrome (MetS) is another cluster of endo-crine disturbances, including insulin resistance,

dyslipide-mia, obesity, central adiposity, and hypertension,(7, 8), that has been associated with a twofold increased risk of cardio-vascular disease and a fivefold increased risk of type 2 diabe-tes(9). Estimates of the prevalence of MetS in women with PCOS have been based mainly on the U.S. population, point-ing to a prevalence of approximately 43% to 46%(10–12). Despite this increased prevalence, the exact relationship between insulin resistance and different features of MetS in PCOS patients is not completely understood.

There are few data concerning this prevalence in other countries, especially in those where obesity is less frequently found than in the United States. Studies involving Czech and Italian women with PCOS report that MetS and its compo-nents were much less frequent in these populations (13, 14), a finding attributed to genetic factors and differences in lifestyle and dietary habits, and, possibly also influenced by the criteria used to diagnose MetS, as well as the criteria used to diagnose PCOS.

In the Brazilian population, the prevalence of obesity, in-creased waist circumference, hypertension, and dyslipidemia is markedly less than observed in the United States (15). Within this context, no data are published on the prevalence Received January 2, 2007; revised and accepted March 28, 2007.

Supported in part by the Conselho Nacional de Desenvolvimento Cientıfico e Tecnologico (CNPq), Ministerio da Saude do Brasil, and

Fundacx~ao de Apoioa Pesquisa do Estado do Rio Grande do Norte (FA-PERN) (Conv^enio 0146.00/04-CNPq/FAPERN, projeto: 673.923254). Reprint requests: George Dantas Azevedo, Ph.D., Departamento de

Mor-fologia do Centro de Bioci^encias, Campus Universitario, BR 101, Lagoa Nova, Natal-RN, Brasil 59078-970 (FAX: þ55-84-32119207; E-mail: georgedantas@uol.com.br).

(2)

Our purpose was to estimate this prevalence according to the National Cholesterol Education Program Adult Treatment Panel III (ATP-III) criteria(16).

MATERIALS AND METHODS Patients

Clinical, anthropometric, biochemical, and hormonal mea-sures were taken of 102 women with PCOS who participated in a cross-sectional study designed to evaluate the association between PCOS and cardiovascular disease. Volunteers were selected at the University Hospital of the Federal University of Rio Grande do Norte, Natal-RN, Brazil, from July 2004 to December 2005. This study was approved by the institutional ethics committee (protocol number 126/04), and all volun-teers gave written informed consent.

Women aged 20 to 34 years who wereR2 years postme-narche were eligible for the study. No classification according to ethnicity was used, as it is very difficult to classify ethnic groups in Brazil where there is abundant racial admixture; the autoreference according to race or color may be not adequate, with significant dissociation of color and genomic ancestry (17, 18).

The diagnosis of PCOS was made according to the criteria of the Rotterdam ESHRE-ASRM–sponsored PCOS consen-sus workshop(4)by the presence of at least two of the follow-ing three features: [1] oligo-ovulation and/or anovulation, characterized by oligomenorrhea (intermenstrual intervals of 45 days or more or fewer than eight menses per year), or amenorrhea (intervals>3 months); [2] clinical signs of

an-drogen excess (Ferriman–Gallwey[19]hirsutism scoreR8 and/or presence of acne), and/or biochemical signs of hyper-androgenism; and [3] ultrasonographic findings of ovarian polycystic morphology (presence of R12 follicles in each ovary measuring 2 to 9 mm in diameter, and/or increased ovarian volume>10 mL)(4).

Infertility was defined as the inability to conceive after 1 year of unprotected intercourse. The exclusion of other disor-ders such as nonclassic congenital adrenal hyperplasia, thyroid dysfunction, and hyperprolactinemia was also con-sidered. Other exclusion criteria for this study were renal or hepatic dysfunction or use of medications known to affect re-productive or metabolic function, such as oral contraceptives, antiandrogen drugs, antidiabetic treatment, statins, or gluco-corticoid therapy within 60 days of study entry. Both Rotter-dam-PCOS criteria and Ferriman–Gallwey score were assessed by at least two observers.

Although many diagnostic criteria for MetS have been pro-posed, the National Cholesterol Education Program Adult Treatment Panel III (ATP-III) criteria are the most commonly used for both clinical and research purposes, so these criteria were adopted for our study as well(16). Thus, the MetS was defined by the presence of three or more of the following ab-normalities: waist circumferenceR88 cm; fasting serum

glu-mg/dL; serum high-density lipoprotein cholesterol (HDL-C)

<50 mg/dL; and blood pressureR130/85 mm Hg.

Study Protocol

All patients underwent a clinical examination where body weight, height, waist and hip circumferences and blood pres-sure were meapres-sured. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in me-ters (kg/m2); overweight was defined as a BMI between 25.0 and 29.9, and obese as 30.0 or higher, according to World Health Organization categories (20). Acanthosis nigricans, a significant marker for insulin resistance (21), was diag-nosed by hyperpigmentation of the skin in the posterior re-gion of the neck, axillae, antecubital fossae, and groin.

Fasting venous blood samples were collected between 8:00 AMand 10:00AMafter a 12-hour overnight fast. Serum glu-cose was measured by the gluglu-cose oxidase method. Levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides, aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyltransfer-ase (GGT), urea, and creatinine were determined by enzy-matic colorimetric assays (BioSystems, Barcelona, Spain). Low-density lipoprotein (LDL) levels were calculated by using Friedewald’s formula.

Blood samples also were obtained at baseline and at 30-minute intervals for 2 hours during a 75-g oral glucose toler-ance test (OGTT) to measure glucose and insulin. Glucose tolerance was evaluated using the American Diabetes Associ-ation’s criteria for the diagnosis and classification of diabetes (22). Insulin sensitivity was evaluated by the quantitative insulin-sensitivity check index (QUICKI): 1/(log insulin [mU/mL]þlog glucose [mg/dL])(23).

Levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and insulin were determined by using commercially available diagnostic kits in the IMMULITE 2000 automated chemiluminescence-immunoassay system (Diagnostic Products Corporation, Los Angeles, CA). Total testosterone, dehydroepiandrosterone sulfate (DHEAS), and 17-hydroxyprogesterone were measured following the manu-facturer’s recommendations (Diagnostic Products Corpora-tion, Los Angeles, CA). Exclusion of nonclassic congenital adrenal hyperplasia was based on a basal morning 17-hydrox-yprogesterone level less than 200 ng/dL.

Statistical Analysis

The normality of distribution of all variables was checked by using the Kolmogorov–Smirnov test. The results were ex-pressed as meanstandard deviation (SD) unless otherwise indicated. The significance of differences between groups was determined using the unpairedt-test and analysis of var-iance (ANOVA), as appropriate. Between-group differences were assessed by chi-square testing. For all analyses, two-tailed P<.05 was considered statistically significant. Data

(3)

RESULTS

Clinical Characteristics of Patients

For the entire cohort, the mean age at baseline evaluation was 26.45.3 years and mean BMI was 29.46.7 kg/m2. The

overall prevalence of women who were overweight or obese was 25.5% (26 out of 102) and 43.1% (44 out of 102), respec-tively. The prevalence rates of oligomenorrhea, hirsutism, and infertility were 56.9%, 41.2%, and 64.7%, respectively.

Prevalence of the Metabolic Syndrome and Glucose Intolerance

The prevalence of MetS in this cohort of 102 women with PCOS was 28.4% (n¼29 patients). A considerable

propor-tion (30.4%) of these women fulfilled two criteria, and 26.5% fulfilled one criteria for MetS. Only 14.7% of them had no MetS factors.Table 1shows the age-stratified preva-lence of MetS, where the increasing prevapreva-lence according to age group can be seen. The prevalence of MetS was also sta-tistically significantly associated with BMI (Table 2). Over-weight and obese women had a sixfold and 16-fold increased risk for MetS, respectively, when compared with

the normal BMI group. High waist circumference and high blood pressure were also more prevalent in the overweight and obese groups (P<.0001).

Based on the 2-hour glucose level during OGTT, glucose tolerance was found to be normal in 80 (78.4%) of the 102 women; 20 (19.6%) had impaired glucose tolerance, and two (2.0%) had noninsulin-dependent diabetes mellitus at the time of baseline evaluation. When we analyzed fasting glucose levels according to the recommendations of the Ex-pert Committee of the American Diabetes Association(22), we found that 99 (97.1%) women had normal fasting glucose (<110 mg/dL), and three (2.9%) had impaired fasting

glu-cose (R110 and<126 mg/dL).

The clinical and metabolic characteristics of subgroups with and without MetS are presented inTable 3. Compared with women without MetS, the patients with MetS had higher BMI, waist circumference, and systolic and diastolic blood pressure as well as higher levels of total cholesterol, triglycer-ides, fasting glucose, fasting insulin, creatinine, and gamma-glutamyltransferase and a lower QUICKI index.

TABLE 1

Age-stratified prevalence of the metabolic syndrome (MetS) in Brazilian women with polycystic ovary syndrome.

Age groups (years) MetS N (%) No MetS N (%) Total N (%)

20–24 4 (12.1) 29 (87.9) 33 (100.0)

25–29 13 (31.7) 28 (68.3) 41 (100.0)

30–34 12 (42.9) 16 (57.1) 28 (100.0)

Total 29 (28.4) 73 (71.6) 102 (100.0)

Note:Prevalence of MetS was different across age groups (chi-square test;P¼.02).

Soares. Metabolic syndrome in Brazilian PCOS. Fertil Steril 2008.

TABLE 2

Prevalence of the metabolic syndrome and individual abnormalities in Brazilian women with polycystic ovary syndrome stratified by body mass index group.

Body mass index (kg/m2)

<25 (n[32) 25 – 29 (n[26) R30 (n[44) Pvaluea

Metabolic syndrome 01 (3.2%) 05 (19.2%) 23 (52.3%) <.0001

High waist circumference 02 (6.3%) 14 (53.8%) 43 (97.7%) <.0001

Hypertriglyceridemia 06 (19.4%) 08 (30.8%) 18 (40.9%) .14

Low HDL-C 18 (62.1%) 19 (76.0%) 34 (85.0%) .09

High blood pressure — 03 (11.5%) 16 (36.4%) <.0001

High fasting glucose — 01 (3.8%) 02 (4.5%) .48

Impaired glucose tolerance 04 (12.5%) 04 (15.4%) 12 (27.3%) .19

NIDDM — — 2 (4.5%) .19

Note:HDL-C, high-density lipoprotein cholesterol; NIDDM, noninsulin-dependent diabetes mellitus. a

Chi-square test.

(4)

The Metabolic Syndrome Abnormalities

The most prevalent isolated MetS abnormality in women with PCOS was high-density lipoprotein cholesterol levels below 50 mg/dL, present in 69.6% (71 out of 102). Other ab-normalities were increased waist circumference in 57.9% (59/102), increased serum triglycerides in 31.4% (32 out of 102), hypertension in 18.6% (19 out of 102), and high fasting glucose concentrations in 2.9% (3 out of 102). Analysis of the prevalence of other PCOS clinical features according to the presence of MetS showed a statistically significant associa-tion with the presence of acanthosis nigricans; the condiassocia-tion was more frequent in women with MetS than in women without MetS (Table 4).

DISCUSSION

In this study, the prevalence of MetS in Brazilian women with PCOS was 28.4%. There are no published references about age-adjusted prevalence of MetS by sex in the general Brazilian population (24). Limited information can be ob-tained from a recent study involving a specific sample of a rural population from Bahia, Brazil, which showed a 7% prevalence of MetS for the 25- to 34-year age group,

with higher frequency in women than in men(25). This lim-itation led us to compare our results with those reported by Ford et al. for the general U.S. population(26). Despite the higher prevalence of obesity in the U.S. population, we found a statistically significant higher prevalence of MetS in our sample of Brazilian women with PCOS than that of U.S. women aged 25 to 34 years.

Several studies have been conducted to evaluate the prev-alence of MetS in women with PCOS. Glueck et al.(10)and Apridonidze et al.(11)observed that the prevalence of MetS in U.S. women with PCOS was 46% and 43%, respectively, much higher than that observed in our study. Conversely, Vrbıkova et al. (13) did not find a higher prevalence of

MetS in Czech women with PCOS, even though those women had higher BMI and waist circumference, higher systolic and diastolic blood pressure, and lower HDL-cholesterol levels than women without PCOS. In Italian women, Carmina et al.(14)observed that MetS was more frequent in women with PCOS than in the general population; however, this prevalence was much lower than in the United States. These differences could be attributed to genetic factors or lifestyle characteristics and dietary habits, such as the higher inci-dence of obesity in the U.S. population.

Comparison of clinical and endocrine characteristics of Brazilian women with polycystic ovary syndrome women with and without the metabolic syndrome (MetS).

Variables MetS (n[29) No MetS (n[73)

Weight (kg) 84.315.0 67.417.1a

Body mass index (kg/m2) 34.25.3 27.56.2a

Waist circumference 101.212.3 86.815.6a

Systolic blood pressure (mm Hg) 125.813.5 109.710.3a

Diastolic blood pressure (mm Hg) 81.010.5 68.99.1a

Prolactin (ng/mL) 13.21.5 15.51.8

TSH (mU/mL) 1.670.14 1.620.21

Serum total testosterone (ng/dL) 114.435.0 105.611.8

DHEAS (ng/dL) 73.323.0 97.416.5

Total cholesterol (mg/dL) 200.639.6 182.541.7a

HDL-C (mg/dL) 37.68.0 42.311.9

LDL-C (mg/dL) 123.739.5 119.240.5

Triglycerides (mg/dL) 196.271.4 103.350.6a

Fasting glucose (mg/dL) 88.314.1 82.210.7a

Fasting insulin (mU/mL) 15.89.2 10.26.5a

QUICKI 0.330.02 0.350.04a

Aspartate aminotransferase (mg/dL) 27.59.4 26.09.8

Alanine aminotransferase (mg/dL) 28.012.4 24.617.7

Gamma-glutamyltransferase (mg/dL) 29.220.9 20.38.1a

Urea (mg/dL) 22.25.2 22.16.0

Creatinine (mg/dL) 1.010.16 0.890.14a

Note:Data presented as meanstandard deviation. DHEAS, dehydroepiandrosterone sulfate; HDL-C, high-density lipo-protein cholesterol; LDL-C, low-density lipolipo-protein cholesterol; QUICKI, quantitative insulin-sensitivity check index; TSH, thyroid-stimulating hormone.

a

Student’s-ttest,P<.001.

(5)

The occurrence of low HDL-C was the most frequent indi-vidual MetS component in Brazilian women with PCOS, fol-lowed by increased waist circumference and increased serum triglycerides. Other studies have reported similar results and point to the fact that dyslipidemia is the most common met-abolic abnormality in PCOS, with a prevalence of up to 70% according to NCEP criteria(6, 11, 27). Furthermore, it is im-portant to observe that the majority of our patients (85.3%) had at least one MetS abnormality, a finding similar to that found by Apridonidze et al.(11).

A very consistent finding is that the prevalence of MetS is highly age and BMI dependent (28, 29). In our study, the prevalence of MetS in women with PCOS aged 20 to 24 years was 12.1%, with a progressive increase to 31.7% in the 25- to 29-year group and 42.9% in the 30- to 34-year group. A previous case-control study involving 86 women with PCOS aged between 18 and 22 years found a MetS prevalence of 11%, supporting the idea that the prevalence of MetS in women with PCOS is high in all age groups (30).

Many women with PCOS (between 38% and 88%) are overweight or obese, and there is no doubt that adiposity plays a crucial role in the development and maintenance of PCOS and strongly influences the severity of both its clinical and endocrine features in many women(31). Obesity seems to contribute as an independent factor for MetS abnormalities (32, 33), and our results are in accordance with this idea, given that increased waist circumference and hypertension showed an increasing prevalence with BMI. Nevertheless, the rates of dyslipidemia and impaired glucose tolerance showed no statistically significant difference among the BMI groups, an important finding corroborating the

rele-vance of screening for MetS and other cardiovascular risk factors in all women with PCOS, regardless of obesity.

Insulin resistance is associated with MetS, and is consid-ered a common denominator of metabolic alterations that characterize the syndrome(34, 35). Our data support this hy-pothesis, with the finding of a statistically significant lower QUICKI index in women with PCOS and MetS when com-pared with those without MetS. Corroborating this finding, we also observed that acanthosis nigricans was more preva-lent in women with PCOS and MetS.

Recently, several clinical, epidemiological, and biochem-ical studies have supported the concept that insulin resis-tance is accompanied by many other alterations that are not included in the diagnostic criteria for MetS. These con-ditions include nonalcoholic fatty liver disease and/or nonal-coholic steatohepatitis, obstructive sleep apnea, and increased levels of prothrombotic factors, homocysteine, and proinflammatory cytokines(8). Results of our observa-tions in women with PCOS show higher gamma-glutamyl-transferase serum levels in women with MetS than in women without MetS, which is in accordance with published data on the subject. Whitfield et al.(36)showed that changes in enzyme gamma-glutamyltransferase and alanine-amino-transferase are associated with cardiovascular risk factors. In the Brazilian population, Araujo et al. (37) found that gamma-glutamyltransferase activity was associated with the number of MetS abnormalities in obese women. Addi-tionally, Setji et al.(38)observed that abnormal aminotrans-ferase activity is common in women with PCOS (about 15%), and is significantly associated to dyslipidemia and hyperinsulinemia. Taken together, these data suggest that women with PCOS may have an increased risk of developing

TABLE 4

Prevalence of clinical characteristics in Brazilian women with polycystic ovary syndrome with and without the metabolic syndrome (MetS).

Prevalence [N (%)]

Variables MetS (N[29) No MetS (N[73) Pvaluea

Amenorrhea 21 (72.4) 58 (79.5) .44

Infertility 18 (62.1) 48 (65.8) .72

Hirsutism 14 (48.3) 29 (39.7) .62

Acanthosis 21 (72.4) 29 (39.7) .005

Polycystic ovary morphology 21 (72.4) 56 (76.7) .89

FH cardiovascular disease 12 (41.4) 34 (46.6) .44

FH systemic

arterial hypertension

24 (82.8) 50 (68.5) .34

FH obesity 15 (51.7) 31 (42.5) .62

FH NIDDM 21 (72.4) 46 (63.0) .51

FH dyslipidemia 13 (44.8) 24 (32.9) .28

Note:FH, family history; NIDDM, noninsulin-dependent diabetes mellitus. a

Chi-square test.

(6)

steatohepatitis.

Despite these relevant findings, it is important to point out the limitations of our study. We included only cross-sectional measures; prospective data from this cohort study will be available in the future to determine conclusively the associa-tion between PCOS and cardiovascular disease in Brazilian women. Other limitations include the relatively small sample size and the fact that only one diagnostic criteria for MetS were considered. Additionally, the results may be influenced by the way in which PCOS and MetS were diagnosed.

The findings of this study confirm that the prevalence of MetS and its individual components, particularly a decreased high-density lipoprotein cholesterol level, is substantially higher in women with PCOS than in the general population. However, the prevalence of MetS in Brazilian women with PCOS appears to be much lower than that found in the U.S. population, as previously reported in other non-U.S. studies. Thus, these women are at increased risk of diabetes mellitus and cardiovascular disease; it is therefore important to screen all women with PCOS for cardiovascular risk fac-tors. Identification and clinical management of this high-risk group is an important aspect of coronary heart disease prevention, and better understanding of these issues is crit-ical to preventing mortality from cardiovascular disease in these patients.

REFERENCES

1. Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333:853–61. 2. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, et al. A survey of the polycystic ovary syn-drome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006–11.

3. Scarpitta AM, Sinagra D. Polycystic ovary syndrome: an endocrine and metabolic disease. Gynecol Endocrinol 2000;14:392–5.

4. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25.

5. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mech-anism and implications for pathogenesis. Endocr Rev 1997;8:774–800. 6. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a

pre-mature association? Endocr Rev 2003;24:302–12.

7. DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and ath-erosclerotic cardiovascular disease. Diabetes Care 1991;14:173–94. 8. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet

2005;365:1415–28.

9. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syn-drome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–52. 10. Glueck CJ, Papanna R, Wang P, Goldenberg N, Sieve-Smith L. Incidence

and treatment of metabolic syndrome in newly referred women with con-firmed polycystic ovarian syndrome. Metabolism 2003;52:908–15. 11. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and

charac-teristics of the metabolic syndrome in women with polycystic ovary syn-drome. J Clin Endocrinol Metab 2005;90:1929–35.

12. Essah PA, Nestler JE. Metabolic syndrome in women with polycystic ovary syndrome. Fertil Steril 2006;86(Suppl 1):S18–9.

et al. Metabolic syndrome in young Czech women with polycystic ovary syndrome. Hum Reprod 2005;20:3328–32.

14. Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA. Metabolic syn-drome in polycystic ovary synsyn-drome (PCOS): lower prevalence in south-ern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol 2006;154:141–5.

15. Marcopito LF, Rodrigues SS, Pacheco MA, Shirassu MM, Goldfeder AJ, Moraes MA. Prevalence of a set of risk factors for chronic diseases in the city of Sao Paulo, Brazil. Rev Saude Publica 2005;39:738–45. 16. Third Report of the National Cholesterol Education Program (NCEP).

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circula-tion 2002;106:3143–421.

17. Parra FC, Amado RC, Lambertucci JR, Rocha J, Antunes CM, Pena SD. Color and genomic ancestry in Brazilians. Proc Natl Acad Sci USA 2003;100:177–82.

18. Pimenta JR, Zuccherato LW, Debes AA, Maselli L, Soares RP, Moura-Neto RS, et al. Color and genomic ancestry in Brazilians: a study with forensic microsatellites. Hum Hered 2006;62:190–5.

19. Ferriman DG, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrino Metab 1961;21:1440–7.

20. World Health Organization. Obesity preventing and managing the global epidemic. Report of a WHO consultation on obesity. Geneva 3–5 June, 1997.

21. Barbieri RL, Ryan KJ. Hyperandrogenism, insulin resistance and acan-thosis nigricans syndrome: a common endocrinopathy with distinct path-ophysiologic features. Am J Obstet Gynecol 1983;147:90–9.

22. Expert Committee on the Diagnosis and Classification of Diabetes Mel-litus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003:26(Suppl 1):S5–20.

23. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402–10.

24. Sociedade Brasileira de Hipertens~ao; Sociedade Brasileira de Cardiolo-gia; Sociedade Brasileira de Endocrinologia e MetaboloCardiolo-gia; Sociedade Brasileira de Diabetes; Sociedade Brasileira de Estudos da Obesidade. I Brazilian guidelines on diagnosis and treatment of metabolic syndrome. Arq Bras Cardiol 2005;84(Suppl 1):1–28.

25. de Oliveira EP, de Souza ML, de Lima MD. Prevalence of metabolic syn-drome in a semi-arid rural area in Bahia. Arq Bras Endocrinol Metabol 2006;50:456–65.

26. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356–9.

27. Sam S, Legro RS, Bentley-Lewis R, Dunaif A. Dyslipidemia and meta-bolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2006;90:4797–802.

28. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med 2003;163:427–36.

29. Alvarez Cosmea A, Lopez Fernandez V, Suarez Garcia S, Arias Garcia T, Prieto Diaz MA, Diaz Gonzalez L. Differences in the prevalence of met-abolic syndrome according to the ATP-III and WHO definitions [in Span-ish]. Med Clin (Barc) 2005;124:368–70.

30. Vural B, Caliskan E, Turkoz E, Kilic T, Demirei A. Evaluation of meta-bolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod 2005;20: 2409–13.

31. Barber TM, McCarthy MI, Wass JA, Franks S. Obesity and polycystic ovary syndrome. Clin Endocrinol (Oxf) 2006;65:137–45.

(7)

33. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. Diabetes Care 2006;22:141–6.

34. Matos AFG, Moreira RO, Guedes EP. Neuroendocrinology of the metabolic syndrome. Arq Bras Endocrinol Metab 2003;47:410– 20.

35. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004;173: 309–14.

36. Whitfield JB, Zhu G, Nestler JE, Heath AC, Martin NG. Genetic covari-ation between serum gamma-glutamyl-transferase activity and cardio-vascular risk factors. Clin Chem 2002;48:1426–31.

37. Araujo LM, Lima DS, Daltro C. Association of gamma-glutamyl trans-ferase and the metabolic syndrome in obese women. Arq Bras Endocri-nol Metab 2005;49:557–62.

Referências

Documentos relacionados

Pregnancy outcome in women with polycystic ovary syndrome comparing the effects of laparoscopic ovarian drilling and clomiphene citrate stimulation in women pre-treated

In view of the above, the aims of this study were to iden- tify the prevalence of MS and its individual components in a population of college students from a public higher

RESUMEN: Tras el impacto en 2005 y afios anteriores y siguientes del primer IV Centena- rio de la publicaci6n de Don Quijote de fa Man cha, la literatura infantil y juvenil entr6

Association between the angiotensin converting enzyme gene insertion/deletion polymorphism and metabolic disturbances in women with polycystic ovary syndrome. Mol

Para a classificação da SM, conforme o critério da IDF, os participantes do estudo deveriam ter, pelo menos, dois componentes adicionais à CC elevada (≥90 cm para homens e ≥80

Objective : to identify the prevalence of the Metabolic Syndrome and its components in people with Type 2 Diabetes Mellitus.. Method : cross-sectional study with 201 people enrolled

Nesse  fragmento,  o  autor  santista  traduz  a  ideia  de imobilidade  por  meio  da  imagem  da  personagem  adormecida, imóvel  diante  do  Outro  e  sem 

Although role model gender and intensity, as well as participant gender did not play a crucial role within the whole model, the following mediation models